Clinical Trial Update: Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML [Phase 1]

View source ↗

Summary

This update describes an ongoing Phase 1 study evaluating Vyxeos plus gilteritinib for relapsed or refractory FLT3-mutated acute myeloid leukemia, currently rec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Acute Myeloid Leukemia with Flt3-itd Mutation

Drugs mentioned

• Gilteritinib (Xospata) (gilteritinib)
• Vyxeos (CPX-351)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Acute Myeloid Leukemia With FLT3/ITD Mutation | Phase 1 | Status: RECRUITING